Frequency recently tweeted an article suggesting that, most of the time, clinical stage biotechs do not have any difficulty getting the funding they need and that the NIH should fund more general "basic science" instead because these are the blueprints research needs to build on before the future profit becomes obvious. It was an interesting take.
If the ATA actually does fund seed grants, that might be a net good to have seed money lauching research at the very early stages, too
It is super frustrating that Hough has to raise funds for their pill but because they are a non-profit, but they might be the exception and not the norm. They might not have the same kind of relationship with biotech investment funds, etc.
All you would need is one wealthy donor with tinnitus to fund the half a million, though, perhaps something like the Gates Foundation or an individual philanthropist who has tinnitus who isn't aware of this drug might help. I wonder if a musicians' organization even would be interested in knowing about the pill.
I so totally agree with you on organizational transparency, though.
I'd just like to see one compelling study that declared funding through the ATA so that a "track record with success" could be substantiated for a condition that has not been cured and consistently displays various mechanisms by which it may act that have not been appropriately followed up on.
Example: Intratympanic Dexamethasone in the Treatment of Acute SSNHL and tinnitus.
-Hold a conference for PCP's and GP's to raise awareness about referring patients with these complaints to trial centers and stress the need for immediacy (<1 month since onset)
-Conduct extended pure-tone audiometry and speech-in-noise tests at baseline
-Record time of patient registration relative to onset
-Deliver the drug on whatever dosing schedule appears most prudent
-Have patient follow-up testing at 1-month, 3-months, 6-months and 12-months post-administration
The fact that there is very little useful scholarly data for the only available preventive intervention for chronic tinnitus is unacceptable. This would be my first move as ATA president. Then you can start looking into comparison vs. placebo (or just cross-examine no-treatment tinnitus progression research), comparison vs. oral prednisone/adjunct therapy, neural imaging, lidocaine MOA's, sleep architecture & effect of REM, etc.
If we had appropriate distribution of grants, companies like Otonomy might not have to waste their time messing with gacyclidine and ChrisBoyMonkey would be better off. I'm not saying OTO-313 will flop, or that dexamethsone treatment is tried-and-true, but that's why you FUND the hell out of it for appropriate scientific understanding. It's cheap as hell, and it makes no sense as to why it's not the first thing on PCP's and ENT's lips when a patient presents with SSNHL.